Baxter recieves warning letter from FDA

The Office of Compliance and Biologics Quality (OCBQ) in the FDA's Center for Biologics Evaluation and Research (CBER) has sent a warning letter to Baxter regarding the company's promotional material for Tisseel general surgery brochure.

The OCBQ claims that the presentation, brochure and sell sheet are false or misleading because these materials, among other things, overstate the efficacy of Tisseel and make unsubstantiated claims of superiority for Tisseel over other conventional hemostatic agents. The OCBQ asked Baxter to cease the dissemination of “violative” promo material for Tisseel.
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.